Total Payments
$29,258
2023 Payments
$64.99
Companies
25
Transactions
65
Medicare Patients
10,687
Medicare Billing
$3.9M
Payment Breakdown by Category
Research$17,555 (60.0%)
Consulting$7,150 (24.4%)
Travel$2,765 (9.5%)
Food & Beverage$1,486 (5.1%)
Education$302.71 (1.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $17,555 | 9 | 60.0% |
| Consulting Fee | $7,150 | 2 | 24.4% |
| Travel and Lodging | $2,765 | 5 | 9.5% |
| Food and Beverage | $1,486 | 40 | 5.1% |
| Education | $302.71 | 9 | 1.0% |
Payments by Type
Research
$17,555
9 transactions
General
$11,703
56 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Eli Lilly and Company | $13,771 | 6 | $0 (2021) |
| Celgene Corporation | $6,879 | 8 | $0 (2022) |
| NOVARTIS PHARMACEUTICALS CORPORATION | $3,784 | 3 | $0 (2018) |
| Exelixis Inc. | $3,336 | 7 | $0 (2017) |
| Pharmacyclics LLC, An AbbVie Company | $217.15 | 2 | $0 (2020) |
| Amgen Inc. | $184.66 | 2 | $0 (2019) |
| JAZZ PHARMACEUTICALS INC. | $119.69 | 2 | $0 (2019) |
| Regeneron Healthcare Solutions, Inc. | $118.73 | 2 | $0 (2019) |
| E.R. Squibb & Sons, L.L.C. | $117.55 | 2 | $0 (2019) |
| GE HealthCare | $103.60 | 1 | $0 (2022) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2023 | $64.99 | 1 | Janssen Biotech, Inc. ($64.99) |
| 2022 | $390.62 | 11 | GE HealthCare ($103.60) |
| 2021 | $128.94 | 5 | Eli Lilly and Company ($88.20) |
| 2020 | $269.29 | 3 | Eli Lilly and Company ($150.00) |
| 2019 | $8,524 | 15 | Eli Lilly and Company ($7,908) |
| 2018 | $8,856 | 12 | Eli Lilly and Company ($5,625) |
| 2017 | $11,025 | 18 | Celgene Corporation ($6,842) |
All Payment Transactions
65 individual payment records from CMS Open Payments — Page 1 of 3
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 04/03/2023 | Janssen Biotech, Inc. | ERLEADA (Drug) | Education | In-kind items and services | $64.99 | General |
| Category: Oncology | ||||||
| 12/27/2022 | Celgene Corporation | Pomalyst (Drug) | Food and Beverage | Cash or cash equivalent | $12.32 | General |
| Category: Hematology | ||||||
| 12/08/2022 | Tactile Systems Technology Inc | Flexitouch Plus (Device), entre | Food and Beverage | In-kind items and services | $56.17 | General |
| Category: PNEUMATIC COMPRESSOR | ||||||
| 12/07/2022 | GE HealthCare | — | Food and Beverage | Cash or cash equivalent | $103.60 | General |
| 11/15/2022 | Adaptive Biotechnologies Corporation | clonoSEQ (Device) | Food and Beverage | In-kind items and services | $24.09 | General |
| Category: B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA | ||||||
| 11/10/2022 | Tactile Systems Technology Inc | Flexitouch Plus (Device), entre | Food and Beverage | In-kind items and services | $16.73 | General |
| Category: PNEUMATIC COMPRESSOR | ||||||
| 11/10/2022 | Tactile Systems Technology Inc | Flexitouch Plus (Device), entre | Food and Beverage | In-kind items and services | $16.73 | General |
| Category: PNEUMATIC COMPRESSOR | ||||||
| 11/08/2022 | Myriad Genetic Laboratories, Inc. | BRAC CDx (Device) | Food and Beverage | Cash or cash equivalent | $12.46 | General |
| Category: Germline DNA Sequencing Hereditary Cancer and Rearrangement Analysis | ||||||
| 10/05/2022 | Daiichi Sankyo Inc. | ENHERTU (Drug) | Food and Beverage | In-kind items and services | $17.54 | General |
| Category: ONCOLOGY | ||||||
| 07/19/2022 | Adaptive Biotechnologies Corporation | clonoSEQ (Device) | Food and Beverage | In-kind items and services | $21.72 | General |
| Category: B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA | ||||||
| 05/12/2022 | Celgene Corporation | Pomalyst (Drug) | Food and Beverage | Cash or cash equivalent | $24.82 | General |
| Category: Hematology | ||||||
| 03/10/2022 | Lilly USA, LLC | VERZENIO (Drug) | Education | In-kind items and services | $84.44 | General |
| Category: Oncology | ||||||
| 10/21/2021 | PUMA BIOTECHNOLOGY, INC. | NERLYNX (Drug) | Food and Beverage | In-kind items and services | $20.66 | General |
| Category: ONCOLOGY | ||||||
| 09/29/2021 | PFIZER INC. | INLYTA (Drug) | Education | In-kind items and services | $8.16 | General |
| Category: ONCOLOGY | ||||||
| 09/07/2021 | Eli Lilly and Company | — | — | In-kind items and services | $38.20 | Research |
| Study: EMONARCHER: A RANDOMIZED, DOUBLE BLIND, PLACEBO-CONTROLLED PHASE 3 STUDY OF ABEMACICLIB PLUS STANDARD ADJUVANT ENDOCRINE THERAPY IN PARTICIPANTS WITH HIGH-RISK, NODE-POSITIVE, HR+, HER2+ EARLY BREAST CANCER WHO HAVE COMPLETED ADJUVANT HER2-TARGETED THERAPY | ||||||
| 06/01/2021 | Gilead Sciences, Inc. | — | Education | In-kind items and services | $11.92 | General |
| 02/26/2021 | Eli Lilly and Company | — | — | In-kind items and services | $50.00 | Research |
| Study: A PHASE 1A/1B STUDY OF LY3484356 ADMINISTERED AS MONOTHERAPY AND IN COMBINATION WITH ABEMACICLIB TO PATIENTS WITH ER+, HER2- LOCALLY ADVANCED OR METASTATIC BREAST CANCER | ||||||
| 08/31/2020 | Eli Lilly and Company | — | — | In-kind items and services | $150.00 | Research |
| Study: A PHASE 1A/1B STUDY OF LY3484356 ADMINISTERED AS MONOTHERAPY AND IN COMBINATION WITH ABEMACICLIB TO PATIENTS WITH ER+, HER2- LOCALLY ADVANCED OR METASTATIC BREAST CANCER | ||||||
| 02/20/2020 | Pharmacyclics LLC, An AbbVie Company | Imbruvica (Drug) | Food and Beverage | In-kind items and services | $118.15 | General |
| Category: Oncology | ||||||
| 01/16/2020 | PFIZER INC. | BOSULIF (Drug), DAURISMO, RUXIENCE | Food and Beverage | In-kind items and services | $1.14 | General |
| Category: METABOLIC DISEASE;ONCOLOGY | ||||||
| 12/24/2019 | JAZZ PHARMACEUTICALS INC. | VYXEOS (Drug) | Food and Beverage | Cash or cash equivalent | $69.69 | General |
| Category: ONCOLOGY | ||||||
| 10/29/2019 | Boehringer Ingelheim Pharmaceuticals, Inc. | GILOTRIF (Drug) | Food and Beverage | In-kind items and services | $12.69 | General |
| Category: ONCOLOGY | ||||||
| 10/10/2019 | Amgen Inc. | — | Food and Beverage | In-kind items and services | $79.20 | General |
| 09/10/2019 | Astellas Pharma US Inc | XTANDI (Drug) | Food and Beverage | In-kind items and services | $18.41 | General |
| Category: ONCOLOGY | ||||||
| 09/04/2019 | E.R. Squibb & Sons, L.L.C. | ELIQUIS (Drug) | Food and Beverage | Cash or cash equivalent | $93.60 | General |
| Category: Cardiovascular | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| A RANDOMIZED, OPEN-LABEL, PHASE 3 STUDY OF ABEMACICLIB COMBINED WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE IN PATIENTS WITH HIGH RISK, NODE POSITIVE, EARLY STAGE, HORMONE RECEPTOR POSITIVE, HUMAN EPIDERMAL RECEPTOR 2 NEGATIVE, BREAST CANCER | Eli Lilly and Company | $10,806 | 2 |
| RESEARCH RELATED PUBLICATION SUPPORT | NOVARTIS PHARMACEUTICALS CORPORATION | $3,784 | 3 |
| MONARCH 2- A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 3 STUDY OF FULVESTRANT WITH OR WITHOUT ABEMACICLIB, A CDK4 6 INHIBITOR, FOR WOMEN WITH HORMONE RECEPTOR POSITIVE, HER2 NEGATIVE LOCALLY ADVANCED OR METASTATIC BREAST CANCER | Eli Lilly and Company | $2,727 | 1 |
| A PHASE 1A/1B STUDY OF LY3484356 ADMINISTERED AS MONOTHERAPY AND IN COMBINATION WITH ABEMACICLIB TO PATIENTS WITH ER+, HER2- LOCALLY ADVANCED OR METASTATIC BREAST CANCER | Eli Lilly and Company | $200.00 | 2 |
| EMONARCHER: A RANDOMIZED, DOUBLE BLIND, PLACEBO-CONTROLLED PHASE 3 STUDY OF ABEMACICLIB PLUS STANDARD ADJUVANT ENDOCRINE THERAPY IN PARTICIPANTS WITH HIGH-RISK, NODE-POSITIVE, HR+, HER2+ EARLY BREAST CANCER WHO HAVE COMPLETED ADJUVANT HER2-TARGETED THERAPY | Eli Lilly and Company | $38.20 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 12 | 299 | 357 | $30,623 | $14,542 |
| 2022 | 49 | 2,717 | 69,558 | $4.4M | $1.1M |
| 2021 | 54 | 3,437 | 73,687 | $4.4M | $1.1M |
| 2020 | 68 | 4,234 | 131,391 | $6.4M | $1.6M |
Total Patients
10,687
Total Services
274,993
Medicare Billing
$3.9M
Procedure Codes
183
All Medicare Procedures & Services
183 procedure records from CMS Medicare Utilization — Page 1 of 8
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 31 | 44 | $6,922 | $4,510 | 65.2% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 52 | 59 | $6,837 | $3,977 | 58.2% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 16 | 24 | $5,456 | $3,355 | 61.5% |
| 80053 | Blood test, comprehensive group of blood chemicals | Office | 2023 | 40 | 47 | $2,914 | $486.45 | 16.7% |
| 85025 | Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | Office | 2023 | 50 | 61 | $2,135 | $464.21 | 21.7% |
| 99212 | Established patient office or other outpatient visit, 10-19 minutes | Office | 2023 | 12 | 12 | $751.22 | $456.30 | 60.7% |
| 36415 | Insertion of needle into vein for collection of blood sample | Office | 2023 | 34 | 38 | $722.00 | $319.20 | 44.2% |
| 86300 | Immunologic analysis for detection of tumor antigen, quantitative; ca 15-3 | Office | 2023 | 14 | 14 | $1,736 | $285.46 | 16.4% |
| 82378 | Carcinoembryonic antigen (cea) protein level | Office | 2023 | 13 | 15 | $1,440 | $278.70 | 19.4% |
| 82728 | Ferritin (blood protein) level | Office | 2023 | 13 | 15 | $870.00 | $200.40 | 23.0% |
| 83550 | Iron binding capacity | Office | 2023 | 12 | 14 | $476.00 | $119.98 | 25.2% |
| 83540 | Iron level | Office | 2023 | 12 | 14 | $364.00 | $88.76 | 24.4% |
| J9271 | Injection, pembrolizumab, 1 mg | Office | 2022 | 17 | 18,800 | $2.6M | $793,001 | 30.1% |
| Q5119 | Injection, rituximab-pvvr, biosimilar, (ruxience), 10 mg | Office | 2022 | 12 | 1,860 | $360,840 | $68,268 | 18.9% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 294 | 696 | $126,220 | $44,260 | 35.1% |
| 96413 | Administration of chemotherapy into vein, 1 hour or less | Office | 2022 | 88 | 346 | $264,081 | $37,294 | 14.1% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 147 | 307 | $82,681 | $29,331 | 35.5% |
| J0897 | Injection, denosumab, 1 mg | Office | 2022 | 17 | 1,620 | $102,660 | $27,743 | 27.0% |
| J1439 | Injection, ferric carboxymaltose, 1 mg | Office | 2022 | 24 | 27,750 | $114,000 | $24,065 | 21.1% |
| G9678 | Oncology care model (ocm) monthly enhanced oncology services (meos) payment for ocm enhanced services. g9678 payments may only be made to ocm practitioners for ocm beneficiaries for the furnishment of enhanced services as defined in the ocm participation a | Office | 2022 | 38 | 103 | $16,480 | $16,453 | 99.8% |
| J0185 | Injection, aprepitant, 1 mg | Office | 2022 | 23 | 8,840 | $79,560 | $11,987 | 15.1% |
| 80053 | Blood test, comprehensive group of blood chemicals | Office | 2022 | 256 | 944 | $58,528 | $9,810 | 16.8% |
| 85025 | Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | Office | 2022 | 301 | 1,278 | $44,730 | $9,778 | 21.9% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2022 | 47 | 54 | $19,618 | $7,649 | 39.0% |
| 82378 | Carcinoembryonic antigen (cea) protein level | Office | 2022 | 107 | 375 | $36,000 | $6,996 | 19.4% |
About Dr. Paul Richards, M.D
Dr. Paul Richards, M.D is a Hematology & Oncology healthcare provider based in Salem, Virginia. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 02/27/2006. The National Provider Identifier (NPI) number assigned to this provider is 1053387266.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Paul Richards, M.D has received a total of $29,258 in payments from pharmaceutical and medical device companies, with $64.99 received in 2023. These payments were reported across 65 transactions from 25 companies. The most common payment nature is "" ($17,555).
As a Medicare-enrolled provider, Richards has provided services to 10,687 Medicare beneficiaries, totaling 274,993 services with total Medicare billing of $3.9M. Data is available for 4 years (2020–2023), covering 183 distinct procedure/service records.
Ad
Practice Information
- Specialty Hematology & Oncology
- Location Salem, VA
- Active Since 02/27/2006
- Last Updated 11/02/2007
- Taxonomy Code 207RH0003X
- Entity Type Individual
- NPI Number 1053387266
Products in Payments
- Revlimid (Drug) $6,842
- KISQALI (Drug) $3,784
- Cabometyx (Drug) $3,336
- Imbruvica (Drug) $217.15
- VYXEOS (Drug) $119.69
- LIBTAYO (Biological) $118.73
- Kyprolis (Biological) $105.46
- ELIQUIS (Drug) $93.60
- Flexitouch Plus (Device) $89.63
- VERZENIO (Drug) $84.44
- ERLEADA (Drug) $64.99
- clonoSEQ (Device) $45.81
- Pomalyst (Drug) $37.14
- GILOTRIF (Drug) $36.19
- ADCETRIS (Biological) $28.82
- OPDIVO (Biological) $23.95
- ZEJULA (Drug) $20.94
- NERLYNX (Drug) $20.66
- XTANDI (Drug) $19.31
- DARZALEX (Biological) $17.74
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Hematology & Oncology Doctors in Salem
Igor Genkin, Md, MD
Hematology & Oncology — Payments: $37,121
Hematology & Oncology $37,121
Dr. Vandana Karri, Md, MD
Hematology & Oncology — Payments: $15,833
Hematology & Oncology $15,833
Dr. Mark Currie, M.d, M.D
Hematology & Oncology — Payments: $15,478
Hematology & Oncology $15,478
Dr. William Pierce, M.d, M.D
Hematology & Oncology — Payments: $9,460
Hematology & Oncology $9,460
Janelle Meyer, Md, MD
Hematology & Oncology — Payments: $7,484
Hematology & Oncology $7,484
John Strother, M.d, M.D
Hematology & Oncology — Payments: $3,216
Hematology & Oncology $3,216